Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerwin Huls

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
Signal Transduction and Targeted Therapy|July 13, 2025
High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerabilityDiego A Pereira-Martins, Isabel Weinhäuser, Emmanuel Griessinger, et al.
Plos One|August 12, 2022
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patientsAbraham Rutgers, Peter E Westerweel, Bronno van der Holt, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Blood Cancer Journal|June 24, 2024
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemiaMaria L Salustiano-Bandeira, Amanda Moreira-Aguiar, Diego A Pereira-Martins, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
American Journal of Human Genetics|November 3, 2015
Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2Celia Zazo Seco, Luciana Serrão de Castro, Josephine W van Nierop, et al.
British Journal of Haematology|October 20, 2022
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemiaDiego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, et al.
International Journal of Laboratory Hematology|September 14, 2020
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failureCelalettin Ustun, Elizabeth A Morgan, Ethan M Ritz, et al.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Signal Transduction and Targeted Therapy|July 13, 2025
High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerabilityDiego A Pereira-Martins, Isabel Weinhäuser, Emmanuel Griessinger, et al.
Plos One|August 12, 2022
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patientsAbraham Rutgers, Peter E Westerweel, Bronno van der Holt, et al.
Blood Cancer Journal|June 19, 2023
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabineJacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, et al.
The Lancet. Haematology|November 1, 2023
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trialMichael Lübbert, Pierre W Wijermans, Michal Kicinski, et al.
Blood Cancer Journal|June 24, 2024
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemiaMaria L Salustiano-Bandeira, Amanda Moreira-Aguiar, Diego A Pereira-Martins, et al.
Haematologica|October 10, 2024
Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapyFederico Mosna, Erika Borlenghi, Mark Litzow, et al.
American Journal of Human Genetics|November 3, 2015
Allelic Mutations of KITLG, Encoding KIT Ligand, Cause Asymmetric and Unilateral Hearing Loss and Waardenburg Syndrome Type 2Celia Zazo Seco, Luciana Serrão de Castro, Josephine W van Nierop, et al.
British Journal of Haematology|October 20, 2022
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemiaDiego A Pereira-Martins, Juan L Coelho-Silva, Isabel Weinhäuser, et al.
International Journal of Laboratory Hematology|September 14, 2020
Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failureCelalettin Ustun, Elizabeth A Morgan, Ethan M Ritz, et al.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Pageof 17